Cite
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
MLA
Muhammed Bulent Akinci, et al. “The Effect of EML4-ALK Break-Apart Ratio on Crizotinib Outcomes in Non-Small Cell Lung Cancer Harboring EML4-ALK Rearrangement.” Journal of Cancer Research and Clinical Oncology, vol. 147, no. 9, Sept. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2be8b11e78714092025b94a6e0de02ef&authtype=sso&custid=ns315887.
APA
Muhammed Bulent Akinci, Nalan Akyürek, Şebnem Yücel, Sadettin Kilickap, Mutlu Hizal, Mehmet Ali Nahit Sendur, Bulent Yalcin, Didem Sener Dede, Cihan Erol, Burak Bilgin, & Gurkan Guner. (2020). The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. Journal of Cancer Research and Clinical Oncology, 147(9).
Chicago
Muhammed Bulent Akinci, Nalan Akyürek, Şebnem Yücel, Sadettin Kilickap, Mutlu Hizal, Mehmet Ali Nahit Sendur, Bulent Yalcin, et al. 2020. “The Effect of EML4-ALK Break-Apart Ratio on Crizotinib Outcomes in Non-Small Cell Lung Cancer Harboring EML4-ALK Rearrangement.” Journal of Cancer Research and Clinical Oncology 147 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2be8b11e78714092025b94a6e0de02ef&authtype=sso&custid=ns315887.